A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...

Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise. The pharmaceutical company reported net income of $5.79 ...

Merck & Co. and Eisai previously had high hopes for their Keytruda-Lenvima combination in a liver cancer subtype based on positive progression-free survival data, but now the combo’s promise has once ...

Prostate cancer is among the most common types of cancer found in men. It develops in the prostate gland, a small organ located just below the urinary bladder and in front of the rectum. According to ...

The identification of 20 causal plasma proteins for prostate cancer represents a critical step toward addressing the need for improved diagnostic specificity and reveals promising new targets for ...

Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) ...

Once E3 tags CYP17A1, the cell uses its proteasome to break down the enzyme entirely. One major advantage of PROTACs is that ...

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Andrea Barnes Andrea Barnes ...